General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis

Article

December 1, 2007

TCIs can come to rescue for AD 'hot spots,' maintenance

With concerns of side-effects from long-term use of topical steroids for atopic dermatitis, topical calcineurin inhibitors including tacrolimus (Protopic, Astellas) and pimecrolimus (Elidel, Novartis) can provide an excellent alternative, offering distinct advantages for long-term therapy over steroids and hitting many of the marks that comprise AD, said Lawrence F. Eichenfield, M.D. An FDA-required black box label warning indicates TCIs only for second-line treatment, but in this manner, TCIs can be particularly beneficial for acute management of flares of eczematous dermatitis; for treatment of "hot spots," and as a maintenance therapy for patients with frequently recurring eczema Dr. Eichenfield explained.